Floatz logo

NALBUPHINE

Abdominal Obesity

Assiut UniversitySmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Abdominal Obesity cohort.

Asset / SponsorPhaseRating
Hydrochlorothiazide
UMC Utrecht
Phase 4BBB
Moxonidine
Baker Heart and Diabetes Institute
Phase 4BB
Elafibranor
Genfit
Phase 2BB
Irbesartan
Baker Heart and Diabetes Institute
Phase 4BB
UMBELLATINE
China National Center for Cardiovascular Diseases
Phase 4BB

View all 27 →

Same molecule, other indications

NALBUPHINE is also rated in:

Pediatric AnesthesiaDormant
BB
Indicative ·
69 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
65 / 100
View asset →
T-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →